Cellectar Biosciences Inc. (CLRB)

2.79 -0.16 (-5.424%)

IEX Real-Time Price

August 14, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 2.95

Price Open 2.99

Volume: 86,241

Avg Volume: 319,802

Market Cap: 10.03M

P/E Ratio -0.01

52 Wk Range 2.52-20.4



CLRB Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
3.4M
276,617
0.73
8.13%

2018-07-13
960,318
141,463
3.20
14.73%

2018-06-29
16.87M
1.25M
2.00
7.43%

2018-06-15
16.87M
1.05M
1.89
6.20%




CLRB Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-11
Q1 2018
N/A
0.00 (0)
-0.21
0.00

2018-05-10
Q1 2018
N/A
0.00 (0)
0.00
0.00

2018-03-22
Q4 2017
BTO
0.00 (0)
-34.00
0.00

2018-03-21
Q4 2017
N/A
0.00 (0)
-34.00
0.00

News

Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review (2018-08-14 08:58 SeekingAlpha)

Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The …

 


Statistics

Shares Outstanding: 3.4M

Top 15 Institution Percent: N/A

Price To Sales: N/A

Price To Book: 2.25

Revenue: N/A

Gross Profit: N/A

Cash: 5.66M

Debt: 6190

Return On Assets: -157.11

Return On Equity: -197.73

Profit Margin: N/A

Price History

Beta: 0.37

50-day Moving Avg: 6.52

200-day Moving Avg: 10.83

YTD Change: -79.64

5-day Change: -10.86

1-month Change: -62.75

3-month Change: -73.43

6-month Change: -76.15

1-year Change: -81.02

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Cellectar Biosciences Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.cellectar.com

Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents.